JNJ-7777120

JNJ-7777120

JNJ-7777120 is a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H4 receptor.<ref name="pmid18639542">Jiang W, Lim HD, Zhang M, et al.,

 Cloning and pharmacological characterization of the dog histamine H(4) receptor, 
 Eur. J. Pharmacol., 
 
 Vol. 592(Issue: 1–3),
 pp. 26–32,
 DOI: 10.1016/j.ejphar.2008.06.095,
 PMID: 18639542,
 
 
 Full text,</ref> It has antiinflammatory effects,<ref>Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, Williams KN, Edwards JP, Karlsson L. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. Journal of Pharmacology and Experimental Therapeutics. 2004 Apr;309(1):404-13. PMID 14722321</ref> and has been demonstrated to be superior to traditional antihistamines in the treatment of pruritus (itching).<ref>Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. Journal of Allergy and Clinical Immunology. 2007 Jan;119(1):176-83. PMID 17208599</ref>

References

This article is a stub related to pharmacology. You can help WikiMD by expanding it!